Stay up to date with the latest developments and advances in HR+/HER2- early breast cancer care with content from key international congresses, expert-to-expert video discussions and breaking news stories.

medwireNews: The 21-gene expression assay may be a poor prognostic aid for premenopausal women aged less than 40 years with luminal B subtype, hormone receptor-positive, HER2-negative early breast cancer, indicates…
medwireNews: Analysis of the monarchE trial suggests that an increase in the burden of diarrhea is the only patient-reported outcome (PRO) to be adversely affected by the addition of abemaciclib…
medwireNews: Dose-dense adjuvant chemotherapy significantly improves the outcomes of individuals with node-positive, early-stage breast cancer relative to the standard schedule, confirm the end-of-study findings from GIM2 presented at the ESMO…
medwireNews: The 10-year findings from the DATA trial have shown no significant benefit of extending aromatase inhibitor (AI) treatment beyond 5 years of sequential therapy in the full study population…
medwireNews: The monarchE investigators have identified baseline factors linked to an increased risk for discontinuation of abemaciclib in the trial comprising patients with hormone receptor-positive, HER2-negative early breast cancer.…
medwireNews: Plasma circulating tumor (ct)DNA analysis could help identify patients with hormone receptor (HR)-positive, HER2-negative early breast cancer who are likely to have distant recurrence at 5 years or more after…
medwireNews: Combining clinicopathologic factors with the luminal A subtype could help identify women with a very low risk for breast cancer local recurrence after breast-conserving surgery, making them good candidates…

Sign up for new content alerts

Enter your email address below and we'll contact you as soon as new content is launched!

HCP confirmation(Required)
Privacy Policy Acceptance(Required)
This field is for validation purposes and should be left unchanged.